Although kinase domain mutations of ErbB receptors are uncommon in acute leukemias, in vitro inhibition of ErbB2 reduces cell proliferation especially when combined with BCR-ABL tyrosine kinase inhibitors in Ph+ ALL, suggesting a role for ErbB signaling pathway activation in leukemia [27, 28]. Here, BCR is linked to acute lymphoblastic leukemia.